Key points are not available for this paper at this time.
Everolimus combined with an aromatase inhibitor improved progression-free survival in patients with hormone-receptor-positive advanced breast cancer previously treated with nonsteroidal aromatase inhibitors. (Funded by Novartis; BOLERO-2 ClinicalTrials.gov number, NCT00863655.).
Building similarity graph...
Analyzing shared references across papers
Loading...
José Baselga
Mario Campone
Martine Piccart
New England Journal of Medicine
Harvard University
University of Toronto
University of California, San Francisco
Building similarity graph...
Analyzing shared references across papers
Loading...
Baselga et al. (Wed,) studied this question.
www.synapsesocial.com/papers/69dff5e12833447a7e2556a4 — DOI: https://doi.org/10.1056/nejmoa1109653